

October 26, 2023



# Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023

SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, after the close of the market, and provide a corporate update.

## ***Conference Call & Webcast:***

**Date:** Thursday, November 9, 2023  
**Time:** 5:00 PM ET  
**Audio Webcast Only:** [link](#)  
**Q&A Participant Registration Link\*:** [link](#)  
(<https://register.vevent.com/register/Blb770b610b0744016870ec2150989ea78>)

\*Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a unique PIN, which are required to access the conference call. They also will have the option to take advantage of a Call Me button and the system will automatically dial out to connect to the Q&A session.

The audio webcast also can be accessed through a link on the Investor Relations section of Aptose's website [here](#). A replay of the webcast will be available on the company's website for 30 days.

The press release, the financial statements and the management's discussion and analysis for the quarter ended September 30, 2023 will be available on SEDAR at [www.sedar.com](http://www.sedar.com) and EDGAR at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml).

## **About Aptose**

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspentinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxetpinib (CG-806), an oral, dual

lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit [www.aptose.com](http://www.aptose.com).

For further information, please contact:

**Aptose Biosciences Inc.**

Susan Pietropaolo  
Corporate Communications & Investor Relations  
201-923-2049  
[spietropaolo@aptose.com](mailto:spietropaolo@aptose.com)

**LifeSci Advisors, LLC**

Dan Ferry, Managing Director  
617-430-7576  
[Daniel@LifeSciAdvisors.com](mailto:Daniel@LifeSciAdvisors.com)



Source: Aptose Biosciences, Inc.